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Patients admitted for acute heart failure (AHF) experience high rates of in-hospital and post-discharge morbidity and mortality despite
current therapies. Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects believed to play
a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX-AHF trial, serelaxin met its primary
endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart
failure (WHF) by 47% through day 5 and both all-cause and cardiovascular mortality by 37% through day 180. RELAX-AHF-2 (ClinicalTrials
.gov NCT01870778) is designed to confirm serelaxin’s effect on these clinical outcomes. RELAX-AHF-2 is a multicentre, randomized,
double-blind, placebo-controlled, event-driven, phase 3 trial enrolling ∼6800 patients hospitalized for AHF with dyspnoea, congestion on
chest radiograph, increased natriuretic peptide levels, mild-to-moderate renal insufficiency, and systolic blood pressure≥125 mmHg. Patients
are randomized within 16 h of presentation to 48 h intravenous infusions of serelaxin (30 μg/kg/day) or placebo, both in addition to standard
of care treatments. The primary objectives are to demonstrate that serelaxin is superior to placebo in reducing: (i) 180 day cardiovascular
death, and (ii) occurrence of WHF through day 5. Key secondary endpoints include 180 day all-cause mortality, composite of 180 day
combined cardiovascular mortality or heart failure/renal failure rehospitalization, and in-hospital length of stay during index AHF. The results
from RELAX-AHF-2 will provide data on the potential beneficial effect of serelaxin on cardiovascular mortality andWHF in selected patients
with AHF.
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Introduction
Acute heart failure (AHF) is the most common cause of hos-
pitalization in patients 65 years and older.1,2 In part due to the
ageing of the population and more effective treatment of chronic
heart failure (HF), its prevalence is expected to increase by
25% over the next 20 years3 and the problem has expanded
*Corresponding author. San Francisco VA Medical Center, Cardiology, 111C, Building 203, Room 2A-49, 4150 Clement Street, San Francisco, CA 94121-1545, USA. Tel: +1 415
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.. worldwide.4,5 Patients hospitalized for HF have a 40–50% rate
of HF exacerbation, of which 10–15% is in-hospital worsening
heart failure (WHF)6–10 and 30–40% is rehospitalization, within
the first 6 months after discharge as well as a 10–15% mortal-
ity rate.11 Compared with ambulatory patients with stable chronic
HF, patients hospitalized for AHF have a dramatic increase in their
risk of death, similar or worse than that after a hospitalization for
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Mechanisms of increased mortality and worsening heart failure (WHF) in acute heart failure.
acute myocardial infarction or stroke.12 Although this increased
risk falls rapidly after discharge, it remains 5- to 10-fold higher than
in ambulatory patients even months after the initial episode.13–15
Potential mechanisms of increased mortality andWHF are outlined
in Figure 1. No evidence of efficacy in reducing morbidity and mor-
tality for any new treatment for patients hospitalized for HF has
been found; hence no change in either treatment or prognosis has
occurred in recent decades.
Serelaxin is a recombinant protein identical in amino acid
sequence and structure to the naturally occurring human peptide
hormone relaxin-2, which is associated with many of the maternal
haemodynamic and renovascular changes that occur in response
to pregnancy, such as systemic and renal vasodilation and increases
in global arterial compliance.16,17 Serelaxin’s activity is initiated by
binding to its cognate receptor, serelaxin family peptide receptor
1 (RXFP1), which is present in the systemic and renal vasculature
as well as in the human heart. Nitric oxide, endothelial endothelin
type B receptor, vascular endothelial growth factor, and cAMP act
as mediators for the vasodilatory as well as anti-fibrotic and anti-
inflammatory effects of serelaxin.16 With these pleiotropic effects
(Figure 2), serelaxin may benefit AHF patients18 not only through
its favourable haemodynamic effects, but also via its protec-
tive effects on the heart, kidney, and other organs, leading to
potential mortality benefits19 as suggested by the data from
RELAX-AHF.20 .
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.. The efficacy and safety of serelaxin as a continuous intravenous
(i.v.) infusion for up to 48 h in AHF patients have been evaluated
in two multicentre, randomized, double-blind, placebo-controlled
trials: (i) the dose-finding phase 2 study Pre-RELAX-AHF,21 and (ii)
the phase 2 registration study RELAX-AHF.19 In both of these trials,
patients were admitted for acute heart failure with persistent dys-
pnoea despite i.v. diuretics with normal-to-elevated systolic blood
pressure (SBP >125 mmHg), congestion on chest radiograph,
elevated natriuretic peptides, and mild-to-moderate renal insuffi-
ciency, and enrolled within 16 h of presentation. The 234 patients
enrolled in Pre-RELAX-AHF were randomized to four doses of
serelaxin ranging from 10 to 250 μg/kg/day or matching placebo.
While each dose suggested some clinical benefit, patients assigned
to serelaxin 30 μg/kg/day had the greatest overall improvement in
signs and symptoms of HF and trends toward improved long-term
outcomes with minimal adverse effects. In the RELAX-AHF study,
1161 patients admitted for AHFwere randomized to receive either
serelaxin (n = 581) or matching placebo (n = 580), both in addi-
tion to standard-of-care AHF treatment. The 48 h i.v. infusion of
serelaxin at the dose of 30 μg/kg/day produced dyspnoea relief as
demonstrated by a 19.4% treatment improvement compared to
placebomeasured over 5 days by visual analogue scale, representing
one of the two primary efficacy endpoints in the study. However,
there was no significant effect on the other primary endpoint of
dyspnoea relief through 24 h measured by a Likert scale. Serelaxin
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Potential mechanisms of beneficial effect of serelaxin in patients with acute heart failure. ET, endothelin; MMP, matrix metallo-
proteinase; NO, nitric oxide; NOS, nitric oxide synthetase; TGF, transforming growth factor; TNF, tumour necrosis factor; VEGF, vascular
endothelial growth factor.
treatment significantly reduced the incidence of WHF through day
5 which was the main component of the improvement in dyspnoea
and contributed to the reduced length of index hospital stay. These
clinical effects were associated with significant improvements in
biomarkers suggestive of less end-organ damage and dysfunction in
serelaxin-treated patients.20 Analysis of all-cause mortality through
day 180 revealed fewer deaths with serelaxin compared to placebo
with a total of 42 [Kaplan–Meier (K–M) estimate, 7.3%] deaths
in the serelaxin group compared to 65 (K–M estimate, 11.3%)
in the placebo group [hazard ratio (HR) 0.63; 95% confidence
intervals (CI) 0.43–0.93; P = 0.020]. The mortality difference was
largely driven by cardiovascular (CV) death through day 180 (K–M
estimates 9.6% and 6.1% in placebo and serelaxin groups, respec-
tively, HR 0.63; 95% CI 0.41–0.96; P = 0.028). Including all patients
treated with serelaxin 30 μg/kg/day from the two trials, CV mor-
tality was reduced by 44% (Figure 3; HR 0.56; 95% CI 0.37–0.86;
P = 0.007). These findings support a sustained benefit of serelaxin
beyond the initial 48 h of administration. Better relief of congestion
and protection from damage to the myocardium, kidneys, and liver
seem the most likely mechanisms for these long-term beneficial
effects.19,20 These results were also consistent with a reduction in
WHF episodes in serelaxin-treated patients. Worsening HF is asso-
ciated with poorer outcomes independently of AHF severity.20
Given that mortality was not a primary efficacy endpoint of
the RELAX-AHF trial, a global, phase 3 trial designed to evaluate
these findings has been initiated. The goal of the second RELAXin
in Acute Heart Failure (RELAX-AHF-2) trial is to confirm the
beneficial effect of serelaxin on 180 day CV death and WHF
through day 5, as well as other relevant clinical outcomes. .
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. Study design and methods
The RELAX-AHF-2 trial (Figure 4) is a multicentre, randomized,
double-blind, placebo-controlled trial to evaluate the efficacy, safety
and tolerability of i.v. infusion of 30 μg/kg/day serelaxin for 48 h,
when added to standard therapy. The trial is event-driven: ∼6800 AHF
patients in 545 centres in 34 countries will be enrolled to obtain at
least 547 confirmed CV deaths. Primary efficacy will be determined
based on the relative risk reductions in CV death through day 180 and
in WHF through day 5. Secondary efficacy endpoints include 180 day
all-cause mortality, length of hospital stay, and CV death or HF/renal
failure rehospitalization through day 180.
The RELAX-AHF-2 Executive Committee (Appendix) designed the
trial and wrote the study protocol in collaboration with the clinical
team from Novartis. The protocol must be approved by the Ethics
Review Committee/Institutional Review Board affiliated with each
centre and is being conducted in accordance with Good Clinical
Practice and the 2002 Declaration of Helsinki. All participants provide
written informed consent. The trial is registered on ClinicalTrials
.gov, NCT01870778). The protocol was amended five times (see
Supplementary material online, Appendix S1).
Study population
The study population includes male and female patients (≥18 years
old) admitted to the hospital for AHF with dyspnoea, congestion on
chest radiograph, elevated BNP or NT-proBNP, normal-to-elevated
SBP ≥125 mmHg, and mild-to-moderate renal impairment [estimated
glomerular filtration rate ≥25 and ≤75 mL/min/1.73 m2, calculated
using the standardized Modification of Diet in Renal Disease (sMDRD)
equation] who are anticipated to require i.v. therapy for at least 48 h
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Rationale and design of the RELAX-AHF-2 trial 803
0 
2 
4 
6 
8 
10 
12 
14 
C
ar
di
ov
as
cu
la
r 
de
at
h 
(%
)
0 30 60 90 120 150 180 
Placebo (n=642) 
Serelaxin 30 μg/kg/day (n=624)
9.8% 
5.6% 
Placebo 
Serelaxin 30 μg/kg/day 
HR: 0.56 
(0.37, 0.86)  
P=0.007 
       # at risk  
624  603  592  574  565  552  470  Serelaxin 
642  616  599  578  552  537  460  Placebo 
Figure 3 Cardiovascular mortality of patients with acute heart failure in the serelaxin programme treated with serelaxin 30 μg/kg/day
compared to placebo.
Figure 4 Schematic diagram of study design for RELAX-AHF-2 trial. HF, heart failure; IV, intravenous.
(Table 1). Patients must remain symptomatic after initial treatment with
at least 40 mg i.v. loop diuretic. Patients receiving i.v. nitrates at a
dose ≤0.1 mg/kg/h with a blood pressure >150 mmHg are eligible.
There is no ejection fraction criterion, such that both HF patients
with preserved (HFpEF) or reduced ejection fraction (HFrEF) are
enrolled. Patients are randomized within 16 h of the earlier of first
administration of i.v. loop diuretic or hospital presentation for the AHF
episode in a 1:1 ratio into the two study arms.
Study treatment
Serelaxin or matching placebo is administered as an i.v. infusion
beginning no more than 4 h after randomization. Infusion continues
for up to 48 h according to a weight range-adjusted dosing regimen
at the nominal dose of 30 μg/kg/day. Similar to the protocol adopted
in the previous Pre-RELAX-AHF and RELAX-AHF trials, blood
pressure is monitored frequently during study drug administration. ..
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. If at any time during the study drug administration the patient’s SBP
decreases by >40 mmHg from baseline but the absolute SBP is ≥100
mmHg in two consecutive measurements 15 min apart, the study drug
infusion rate is decreased by 50% for the remainder of the infusion
period. If the patient’s SBP falls to <100 mmHg in two consecutive
measurements 15 min apart, the study drug is permanently discon-
tinued. Randomized patients are required to receive standard-of-care
background HF management during both the index hospitalization and
the follow-up period of 180 days. After randomization, the investigator
may prescribe any additional medications dictated by the patients’
condition, including i.v. loop diuretics and vasoactive medications.
Study assessments
Patients are assessed daily while hospitalized through day 5 or
discharge, whichever comes first. They are also assessed at days 14,
60, 120 (phone contact), and 180 (Table 2). Heart failure signs and
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Rationale and design of the RELAX-AHF-2 trial 805
symptoms are assessed through day 60, and local haematology and
clinical chemistry tests performed through day 5. Adverse events are
reported from signing of the informed consent form through day 5 for
non-serious adverse events and through day 14 for serious adverse
events. All deaths and hospitalizations reported through day 180 are
adjudicated by a Clinical Events Committee (Appendix). Rehospitaliza-
tion is defined as an unplanned hospitalization (including admission to
a hospital or any attendance in an acute care setting, e.g. emergency
department, or in another health care facility) of 24 h or greater,
regardless of whether the patient was admitted to the hospital.
The occurrence of WHF is reported by the investigator through
day 5 post-randomization, and is defined as worsening signs and/or
symptoms of HF that require an intensification of i.v. therapy or
mechanical ventilatory, renal or circulatory support for HF. Such
treatment can include the institution or up-titration of i.v. diuretic,
i.v. nitrates, or any other i.v. medication for HF, or institution of
mechanical support such as ventilation, ultrafiltration, haemodialysis,
intra-aortic balloon pump, or ventricular assist device. Worsening HF
can occur within the 5 day post-randomization period either during the
index admission, or after discharge as an unplanned rehospitalization
or unscheduled physician office/emergency department visit due to a
primary diagnosis of HF. This endpoint also includes patients who die
in this 5 day period from any cause.
ECGs are performed and interpreted locally for all patients at
screening and at day 5 or discharge, whichever occurs first. In addi-
tion, ECGs are performed locally and interpreted by a central core
lab at baseline and end of study infusion in a substudy of at least
500 patients in selected centres to evaluate the impact of serelaxin
on ECG variables. Samples through day 14 are collected for central
haematology, blood chemistry, and biomarker assays in ∼1600 patients
at selected centres.
Statistical considerations
Primary and secondary efficacy outcomes, except all-cause mortality,
will be compared between treatment groups on an intent-to-treat basis
using a sequentially rejective multiple testing procedure22 controlling
the overall two-sided 𝛼 at 5%. Treatment groups will be compared
regarding the time to CV death through day 180 with a log-rank test
at an initial significance level of (4/5)𝛼, and regarding time to WHF
through day 5 at an initial significance level of (1/5)𝛼 using a Gehan’s
generalized Wilcoxon test. All-cause mortality will be tested inde-
pendently at the two-sided 5% significance level, if the test of either
or both of the primary endpoints is significant. The significance level
for the final test will be adjusted to account for the interim efficacy
analysis, planned to occur after ∼60% (i.e. 329) of confirmed CV
deaths have accrued. A Lan–DeMets spending function approximating
an O’Brien–Fleming stopping boundary will be employed to control
the overall one-sided statistical testing of the CV mortality endpoint
at the 2% level and the interim analysis will only be performed on the
CV mortality endpoint. An independent Data Monitoring Committee
(Appendix), supported by an independent, unblinded statistical centre,
regularly reviews safety data as well as the interim efficacy analysis.
Accounting for the one interim efficacy analysis, 547 confirmed CV
deaths are needed for 80% power to detect a 22% relative risk reduc-
tion. Assuming the 180 day CV death rate is 9.0% in the placebo group,
which is ∼80% of 11.3% of all-cause death observed in the placebo
group in RELAX-AHF,19 ∼6800 patients will need to be enrolled. The
observed overall rate of the primary CV mortality endpoint will be
assessed on a blinded basis, and adjustments to patient enrolment
made in order to achieve the required number of events. Using the ..
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.. proposed multiple testing procedure, the power for WHF is at least
80% with the sample size of 6800 assuming at least a 20% relative risk
reduction with 12.2% placebo event rate based on RELAX-AHF data.
Discussion
Over the last two decades, morbidity and mortality from chronic
HFrEF has decreased dramatically with the adoption of ACE
inhibitors/angiotensin receptor blockers, beta-blockers, and min-
eralocorticoid receptor antagonists. These therapies comprise
the cornerstone of pharmacological chronic HF treatment. More
recently, further progress has been made with the addition of an
angiotensin receptor/neprilysin inhibitor (ARNI) as an alternative
to ACE inhibitors, and ivabradine as an adjunct to maximally toler-
ated beta-blocker therapy in patients in sinus rhythm.1,23 However,
these patients remain at high risk for acute decompensation, an
event associated with a marked increase in mortality and HF
recurrence either in the form of in-hospital or post-discharge
WHF. Despite the urgent need to improve the outcomes of
patients with AHF, only three therapies have gained regulatory
approval in the last two decades: i.v. milrinone and nesiritide in the
US and levosimendan in Europe.1,2 Despite their approval, none
of these drugs has demonstrated favourable effects on outcomes.
Current treatment of AHF is based on drugs that have limited
evidence of efficacy based on formal randomized controlled data.
While diuretics have a Class I recommendation with a C level
of evidence for the treatment of patients with congestion for
symptom relief, other therapies such as nitrates have Class IIa
recommendations with a B level of evidence.1 None of these
therapies has an indication for improvement in clinical outcomes.
On the other hand, trials of novel therapies for AHF have
failed to significantly improve symptoms or outcomes.24 Given the
number of failures, variables other than the drug itself may have
influenced these results. The heterogeneity of AHF patients, the
inclusion of patients with non-cardiac causes of symptoms, and the
failure to align the drug’s mechanism of action with the optimal
patient population most likely to benefit from the study treatment
are also potentially contributing causes.
To address these limitations, the RELAX-AHF trials have
enrolled patients admitted for AHF with persistent symptoms well
defined by objective clinical diagnostics, including congestion on
chest radiograph and elevated natriuretic peptide plasma levels.
The patients are required to remain symptomatic despite initial
treatment with i.v. diuretics, and in RELAX-AHF-2 only patients
with severe enough AHF anticipated to require 48 h of i.v. therapy
are enrolled. The inclusion of at least mild renal dysfunction among
the entry criteria allows selection of a higher-risk patient popula-
tion, where serelaxin’s potential renoprotective properties could
provide benefit.20,25 Enrolling patients with normal-to-elevated
blood pressure (SBP ≥125 mmHg) selects patients most likely to
benefit from the vasodilatory properties of serelaxin and those
less likely to suffer from the untoward effects of hypotension.
Drug-induced hypotension has been a major cause of failure in
previous AHF trials.9,26 Whether serelaxin could provide benefit
to patients with lower blood pressures or initial evidence of
compromised perfusion can be addressed in future clinical studies
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and clinical practice. Enrolling patients early enough to maximize
the potential end-organ protective and haemodynamic benefits of
serelaxin, yet late enough to be confident in the diagnosis of AHF,
is central to the design of the RELAX-AHF trials. Other studies
that focused on dyspnoea relief suggested that earlier initiation of
therapy provides greater symptom relief.27 However, in one study,
only two-thirds of the enrolled patients with a suspected diagnosis
of AHF within 1 h of presentation were confirmed to have AHF at
6 h after presentation, suggesting that too rapid enrolment might
result in patients without AHF being included in the trial.28 In both
Pre-RELAX-AHF21 and RELAX-AHF19 patients were randomized
within 16 h of presentation at a median of 8–9 h; this time frame
is the goal for RELAX-AHF-2 as well.
In contrast with studies in patients with chronic HF where a
reduced ejection fraction has been a useful criterion for patient
selection, the serelaxin trials enrolled patients with both HFrEF
and HFpEF.19,21 This is consistent with previous trials testing drugs
acting on peripheral vessels and/or renal function in patients with
AHF.29,30 The prognosis of the patients with AHF was not found
to be related to left ventricular ejection fraction31 and a similar
benefit of serelaxin on clinical outcomes was observed in both
patients with preserved and reduced ejection fraction.32 However,
to provide additional information on the potential beneficial
effects of serelaxin in these groups of patients, echocardiograms
are obtained during the index hospitalization in RELAX-AHF-2.
The timing of the echocardiograms was not specified, since a prior
study suggested that left ventricular function does not change
significantly in these types of AHF patients33 and it would be unde-
sirable to have the echocardiogram interfere with randomization
and initiation of study drug.
There is no limitation on concomitant oral therapies during
study drug administration, but i.v. vasoactive therapies are either
excluded or limited. Given the entry criterion of SBP ≥125 mmHg,
there is no indication for vasopressors or inotropic agents, and
while relatively safe, nesiritide has demonstrated no clinical benefits
and has limited regulatory approval globally. Intravenous nitrates
are the only i.v. vasoactive drugs allowed in addition to diuretics
at the time of enrolment. Despite lack of evidence about their
efficacy in the treatment of AHF34 and a recent guideline specifically
stating, ‘Do not routinely offer nitrates to people with AHF’,35
many authorities continue to support their use. This may be
especially true in patients with increased blood pressure at the
time of randomization and hence, administration of i.v. nitrates
was allowed only in this subgroup of patients (i.e. SBP >150
mmHg at the time of screening). The dose of nitrates allowed in
RELAX-AHF-2 is clinically relevant and not particularly restrictive;
an 80 kg person could be receiving up to 133 μg/min nitroglycerin
or three times the dose achieved in VMAC,36 and over 6–10 times
the recommended starting dose of the ESC guidelines.1
While few would challenge the clinical importance of reducing
CV mortality, some have questioned the biological plausibility of
a 48 h infusion of any drug having a significant effect on 180
day mortality in patients with AHF. While the ability of a brief
infusion of a thrombolytic can clearly improve survival in patients
with acute myocardial infarction, our understanding of AHF has
not yet revealed a similarly specific ‘clot’ to target. However, an ..
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.. emerging concept of AHF as a combination of a haemodynamic,
neurohormonal, inflammatory, and cytokine storm that results in
small, but clinically significant end-organ damage suggests that early
and effective interventions could have long-term, beneficial effects.
Results from RELAX-AHF support this hypothesis,19,20 where
evidence of myocardial, renal, liver, and other organ protection
by serelaxin was associated with a 37% reduction in both CV and
all-cause mortality. In addition, there is evidence to support the
converse, where a 48 h infusion of milrinone decreased long-term
survival compared to placebo with the survival curves continuing
to diverge beyond the infusion.37 While the Pre-RELAX-AHF and
RELAX-AHF studies suggest a survival advantage of serelaxin in
patients with AHF, mortality was not a primary endpoint in either
study and the HF literature is replete with programmes that have
failed to confirm early signals of improved survival. Consequently,
RELAX-AHF-2 is appropriately powered to detect a clinically
meaningful 22% reduction in risk of CV mortality.
While reducing CV mortality is an undisputedly important goal,
WHF has only more recently emerged as a clinically meaningful
endpoint in itself with increasing recognition also by regulators.
In-hospital WHF is generally defined as WHF symptoms and signs
requiring an intensification of therapy,8,10,38–41 and occurs in a vari-
able proportion of patients admitted for AHF, ranging from 5 to
42%.41 Worsening HF is associated with a prolonged length of hos-
pitalization, increased release of biomarkers related to myocardial
damage and renal dysfunction and, more importantly, with a poorer
long-term outcome both with respect to rehospitalizations and
mortality. The clinical importance of WHF has been demonstrated
in retrospective analyses of patient databases and intervention tri-
als, as well as in a recent pooled analysis of 3691 patients from AHF
trials.42 The occurrence of WHF is also sensitive to treatment as it
may be reduced by drugs active on symptoms in the patients with
AHF,9 and serelaxin treatment in RELAX-AHF was associated with
a 30% decrease in WHF within 14 days. Due to these encouraging
results and the importance of this event to patients, RELAX-AHF-2
was designed from its initiation to include robust report forms
and detailed documentation to appropriately collect and charac-
terize WHF events, an endpoint elevated from exploratory in
RELAX-AHF to key secondary in RELAX-AHF-2 since the trial
initiation. Moreover, after a strategic reconsideration following
the reviews of marketing authorization applications submitted
based on RELAX-AHF results to health authorities worldwide and
after further consultations with regulators, the Sponsor and the
Executive Committee decided to further elevateWHF through day
5 to a second primary endpoint in RELAX-AHF-2, in addition to
CV mortality through day 180. Thus, RELAX-AHF-2 is designed to
definitively assess the effect of serelaxin on WHF as an additional
primary endpoint of the trial.
In conclusion, RELAX-AHF-2 is expected to answer a key
question in AHF therapeutics: can a 48 h infusion of serelaxin
reduce 180 day CV mortality of patients admitted for AHF or
reduce the occurrence of WHF? If this question is answered
in agreement with previous evidence from Pre-RELAX-AHF and
RELAX-AHF, it will revolutionize therapy for patients with AHF
and for the first time provide an addition to the AHF therapeutic
armamentarium with definitive outcome data.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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